Skip to Main Content

Author Details

Joseph E. Oesterling
Mayo Clinic
1986
222
68
PMIDPaper TitleJournal TitlePublished Year
10604382Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.J Urol2000
10379751Have complication rates decreased after treatment for localized prostate cancer?J Urol1999
10411025Prostate specific antigen: a decade of discovery--what we have learned and where we are going.J Urol1999
9697777Understanding artificial neural networks and exploring their potential applications for the practicing urologist.Urology1998
9474183A model for the number of cores per prostate biopsy based on patient age and prostate gland volume.J Urol1998
9663202Transurethral needle ablation of the prostate: a minimally invasive treatment for symptomatic benign prostatic hyperplasia.Mayo Clin Proc1998
9610564Percent free prostate-specific antigen: the next frontier in prostate-specific antigen testing.Urology1998
9609620Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.Urology1998
9511773Benign prostatic hyperplasia: use of drug therapy in primary care.Geriatrics1998
9510346Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study.Urology1998
9554360A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia.J Urol1998
9586598Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group.Urology1998
9674714Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists.Am J Med1998
9576570Serum percent-free PSA does not predict extraprostatic spread of prostate cancer.Am J Clin Pathol1998
9836538Reference ranges for serum prostate-specific antigen in black and white men without cancer.Urology1998
9697778Screening digital rectal examination and prostate cancer mortality: a population-based case-control study.Urology1998
9000179Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.Urology1997
12735828Enhancing PSA performance in the diagnosis of prostate cancer.Can J Urol1997
9127226Diagnosis and treatment of benign prostatic hyperplasia. Practice patterns of primary care physicians.J Gen Intern Med1997
9224330A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer.J Urol1997
9126236Using prostate-specific antigen to eliminate the staging radionuclide bone scan.Urol Clin North Am1997
9126235Use of prostate-specific antigen, Gleason score, and digital rectal examination in staging patients with newly diagnosed prostate cancer.Urol Clin North Am1997
9126233Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen.Urol Clin North Am1997
9126232Age-specific reference ranges for serum prostate-specific antigen.Urol Clin North Am1997
9126230Prostate-specific antigen density.Urol Clin North Am1997
9126225The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration.Urol Clin North Am1997
9218012Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group.Urology1997
9121181Percent free prostate-specific antigen: entering a new era in the detection of prostate cancer.Mayo Clin Proc1997
9214675Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study.J Natl Cancer Inst1997
9258062Update on the appropriate staging evaluation for newly diagnosed prostate cancer.J Urol1997
9161345The decision to seek care. Factors associated with the propensity to seek care in a community-based cohort of men.Arch Fam Med1997
9111627Autologous blood donation prior to anatomical radical retropubic prostatectomy: is it necessary?Urology1997
9111615Analysis and presentation. Clinical trials on prostate cancer.Urology1997
9145716Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.JAMA1997
9186314The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues.J Urol1997
11066505Medical malpractice implications of PSA testing for early detection of prostate cancer.J Law Med Ethics1997
9436284Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy.World J Urol1997
9338731Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial.Urology1997
7490873The effect of finasteride on prostate specific antigen: review of available data.J Urol1996
12118563Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens.Int J Radiat Oncol Biol Phys1996
8973706In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples.Urology1996
8973699Multicenter comparison of the diagnostic performance of free prostate-specific antigen.Urology1996
8973698Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy.Urology1996
8973692The clinical usefulness of percent free-PSA.Urology1996
8973671Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.Urology1996
8905498Interpreting results of prostate-specific antigen testing for early detection of prostate cancer.J Gen Intern Med1996
8944739Predictive properties of serum-prostate-specific antigen testing in a community-based setting.Arch Intern Med1996
8753736Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate.Urology1996
8753735Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study.Urology1996
8886054Recommendations of the first Michigan conference on prostate cancer.Urology1996
  • 1 - 50 of 222

Recommended Authors

university of california san diego Moores Cancer Center
Career Start Year 2001
Number of shared co-authors 6
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1997
Number of shared co-authors 2
The Royal Marsden NHS Foundation Trust
Career Start Year 1996
Number of shared co-authors 1
David Geffen School of Medicine at university of california los angeles
Career Start Year 1993
Number of shared co-authors 4
University Health Network, Princess Margaret Cancer Center, University of Toronto
Career Start Year 1993
Number of shared co-authors 1
University Hospital Frankfurt, Goethe University Frankfurt am Main
Career Start Year 1993
Number of shared co-authors 5
Washington State University Elson S. Floyd College of Medicine
Career Start Year 1992
Number of shared co-authors 3
Yonsei University College of Medicine and Gangnam Severance Hospital
Career Start Year 1992
Number of shared co-authors 1
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 3
Hospitalier Universitaire de Saint-Etienne
Career Start Year 1989
Number of shared co-authors 2
University of Toronto
Career Start Year 1989
Number of shared co-authors 5
University of Melbourne
Career Start Year 1988
Number of shared co-authors 1
Liverpool University Hospitals
Career Start Year 1988
Number of shared co-authors 0
University of California Davis
Career Start Year 1988
Number of shared co-authors 3
Skane University Hospital, Lund University
Career Start Year 1987
Number of shared co-authors 2
McGill University Health Centre, McGill University
Career Start Year 1987
Number of shared co-authors 0
University of Oxford
Career Start Year 1987
Number of shared co-authors 5
Yale University School of Medicine
Career Start Year 1986
Number of shared co-authors 3
PolyClinic St. Moritz/Scuol
Career Start Year 1986
Number of shared co-authors 1
Cleveland Clinic
Career Start Year 1984
Number of shared co-authors 7
Johns Hopkins University School of Medicine
Career Start Year 1984
Number of shared co-authors 4
University of Western Ontario
Career Start Year 1982
Number of shared co-authors 3
University of Oxford, John Radcliffe Hospital
Career Start Year 1981
Number of shared co-authors 3
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 6
University Hospitals Leuven
Career Start Year 1981
Number of shared co-authors 3
University of Washington School of Medicine
Career Start Year 1980
Number of shared co-authors 6
Royal Melbourne Hospital
Career Start Year 1974
Number of shared co-authors 2
University Health Network, University of Toronto
Career Start Year 1974
Number of shared co-authors 2
Martini-Klinik Prostate Cancer Center, University Hospital-Hamburg-Eppendorf
Career Start Year 1971
Number of shared co-authors 7
University of Toronto, University Health Network
Career Start Year 1971
Number of shared co-authors 2

Collaborators

Kaiser Permanente Southern California
Co-authored papers 35
Mayo Clinic College of Medicine
Co-authored papers 33
University of North Carolina at Chapel Hill
Co-authored papers 30
University of North Carolina at Chapel Hill
Co-authored papers 23
Section of Health Services Evaluation, Mayo Clinic
Co-authored papers 20
Brown University, Brown University Warren Alpert Medical School, Dartmouth-Hitchcock Medical Center, Harvard School of Public Health, Johns Hopkins Medicine, Mayo Clinic Minnesota
Co-authored papers 19
Mayo Clinic
Co-authored papers 19
Mayo Clinic
Co-authored papers 11
The Brady Urological Institute, Johns Hopkins University School of Medicine
Co-authored papers 9
Merck & Co., Inc.
Co-authored papers 7
Division of Clinical Chemistry, Johns Hopkins University
Co-authored papers 7
Mayo Clinic
Co-authored papers 5
Mayo Clinic
Co-authored papers 4
Mayo Clinic
Co-authored papers 4
Massachusetts General Hospital
Co-authored papers 4
Co-authored papers 4
Deverka Consulting LLC
Co-authored papers 3
Mayo Clinic
Co-authored papers 3
Epstein Health LLC
Co-authored papers 3
College of Public Health, University of South Florida
Co-authored papers 2
CHRISTUS Santa Rosa Hospital-Medical Center
Co-authored papers 2
School of Public Health, 4University of Washington
Co-authored papers 2
Mayo Clinic
Co-authored papers 2
University of Edinburgh
Co-authored papers 1
Boston University School of Public Health.
Co-authored papers 1
University of Washington
Co-authored papers 1
Co-authored papers 1
Duke University School of Medicine, and the Duke Cancer Institute
Co-authored papers 1
Co-authored papers 1
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 1